CN115569173A - Medicine for treating diabetic foot - Google Patents

Medicine for treating diabetic foot Download PDF

Info

Publication number
CN115569173A
CN115569173A CN202211349515.3A CN202211349515A CN115569173A CN 115569173 A CN115569173 A CN 115569173A CN 202211349515 A CN202211349515 A CN 202211349515A CN 115569173 A CN115569173 A CN 115569173A
Authority
CN
China
Prior art keywords
parts
root
pollen
diabetic foot
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202211349515.3A
Other languages
Chinese (zh)
Inventor
席许林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202211349515.3A priority Critical patent/CN115569173A/en
Publication of CN115569173A publication Critical patent/CN115569173A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/634—Forsythia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/739—Sanguisorba (burnet)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a medicine for treating diabetic foot, which comprises a first medicine composition and a second medicine composition, wherein the first medicine composition consists of cherokee rose root, garden burnet root, japanese sage root, raspberry, bird seed, dragon bone, pollen, weeping forsythia, schisandra fruit, fragrant solomonseal rhizome, dried rehmannia root and ramie root; the first external medicine composition can directly act on the external wound surface, astringe and promote tissue regeneration, sterilize and disinfect, quickly reduce the area of the wound surface, reduce the infection probability of the wound surface, treat both internally and externally, and combine two phases, so that the ulcerated wound can be healed quickly, the treatment course is shortened, and the treatment effect is improved.

Description

Medicine for treating diabetic foot
Technical Field
The invention relates to the technical field of medicines, in particular to a medicine for treating diabetic foot.
Background
Diabetic foot is one of the serious complications of diabetes, and is often seen in middle-aged and elderly people with long course of disease and poor blood sugar control. The early stage of the disease is manifested by numbness of limbs, coolness, decreased sensory ability, easy injury, difficult wound healing, frequent neglect and rapid deterioration of the later stage, and the amputation is likely to be faced within one week, and the death rate reaches 10% within one month after amputation.
The diabetic patients can cause the damage and deformity of foot soft tissues and bone joint systems due to the combination of blood circulation disorder and peripheral neuropathy with too high mechanical pressure, thereby causing a series of foot problems from mild neurological symptoms to severe ulcers, infections, blood vessels, neuropathy, diabetic gangrene, osteomyelitis, osteonecrosis and fractures. Many of the foot complications in patients arise from sensory neuropathy and mild autonomic and motor neuropathy. Where sensory neuropathy combined with excessive mechanical stress is a major initiating factor in causing foot ulcers and infections. Inflammation and tissue damage are the result of a certain degree of repetitive stress on a particular area of loss of sensation. Autonomic dysfunction causes damage to the skin soft tissue, resulting in invasion of foreign bacteria. In addition, hyperglycemia, platelet adhesion, reduced oxygen partial pressure, and malnutrition, among others, can collectively cause tissue edema, acid accumulation, hypertonicity, and inefficient anaerobic metabolism, such environments being suitable for bacterial growth. In addition, vascular disease can cause limited antibiotic action, further resulting in reduced bacterial clearance efficiency, resulting in non-healing of local soft tissue infections and even the development of osteomyelitis, which ultimately necessitates amputation.
Diabetic foot was graded according to Wagner:
stage I: it is a superficial ulcer, most commonly found in the 1 st phalanx. The method is characterized in that: red wound, the granulation of wound surface is bright red, and the edge is neat; does not penetrate the dermis layer; maceration of the skin surrounding the wound; 5-10 ml of middle equivalent infiltration liquid.
And II, stage: deep ulcers, which often pass through subcutaneous fat to the fascia or ligament, do not have abscess formation and bone involvement. For I and II grade pathological changes, neuropathy and vasculopathy should be evaluated in time clinically, and ulcer deep secretion is removed to perform bacteria culture and drug sensitivity test. The method is characterized in that: the yellow color of the wound is 100 percent, subcutaneous fat necrosis is accompanied with yellow purulent secretion, and the medium-equivalent amount of exudate is 5 to 10ml.
And (3) stage III: the deep ulcer is accompanied by infection such as cellulitis or abscess, bone is affected, osteomyelitis is often caused, wound tissue and blood culture should be carried out on the wound in time, and anti-infection treatment is carried out according to the culture result. The method is characterized in that: wound bed 75% yellow, 25% red; the skin around the wound is red, swollen, hot, painful and soaked, the basal bone tendon is exposed, the sinus tract is hidden and absent, and the bone damage is shown by X-ray; the seepage amount is more than 10ml.
IV stage: the local gangrene at the toe, heel or far end in a larger range is fully evaluated to determine whether obvious vascular lesions exist and the degree and range of the vascular lesions. The method is characterized in that: black wounds, with ischemic necrotic tissue often associated with brown, tan or black crusts, foot gangrene; ABI checks for dorsalis pedis artery occlusion.
And V stage: gangrene of all feet.
The problems that patients with diabetic foot have low self-repairing and antibacterial functions and infection and wounds are difficult to repair and self-heal make the treatment of diabetic foot become a medical problem to be solved urgently. Diabetic foot ulcers are the first of four persistent complications recognized in the world, and in recent years, the prevalence and treatment cost of diabetic foot ulcers have rapidly increased, thus causing high importance to the medical field. So far, no effective treatment technical scheme and means for treating the diabetic foot are summarized at home and abroad. At present, western medicine mainly uses antibiotics to resist infection, and adopts means such as medicines, operations, local debridement, novel external application materials, stem cell transplantation, high pressure oxygen and the like, but the problem of healing of the wound surface of the diabetic foot cannot be fundamentally solved. And some oral traditional Chinese medicines have long treatment course, so that the wound surface can not be quickly healed, the wound surface is very easy to continue to be infected by bacteria, and the treatment effect is not ideal.
Disclosure of Invention
Therefore, based on the background, the invention provides the medicine for treating the diabetic foot, which adopts the traditional Chinese medicine composition for oral administration and external application to treat the diabetic foot internally and externally, promotes the rapid healing of the wound surface, shortens the treatment course and improves the curative effect.
The technical scheme provided by the invention is as follows:
a medicine for treating diabetic foot comprises a first medicine composition and a second medicine composition, wherein the first medicine composition is composed of the following raw medicines in parts by weight:
10-50 parts of cherokee rose root, 10-50 parts of garden burnet root, 10-50 parts of Japanese notoginseng, 5-50 parts of raspberry, 20-70 parts of henbane root, 5-40 parts of dragon bone, 5-40 parts of pollen, 5-40 parts of weeping forsythia, 5-40 parts of Chinese magnoliavine fruit, 5-40 parts of fragrant solomonseal rhizome, 5-40 parts of radix rehmanniae and 10-50 parts of ramie root;
the second medicinal composition consists of borax, dried alum, borneol, calomel, pollen and cutch, and the dosage ratios of the borax, the dried alum, the borneol, the calomel, the pollen and the cutch are respectively as follows: 0.5-2:0.5-2:0.5-2:0.2-1:0.5-2:0.5-2.
Preferably, the first pharmaceutical composition is composed of the following raw material medicines in parts by weight:
20-30 parts of cherokee rose root, 20-30 parts of garden burnet root, 20-30 parts of panax notoginseng, 10-20 parts of raspberry, 30-50 parts of henbane root, 10-20 parts of dragon bone, 10-20 parts of pollen, 10-20 parts of weeping forsythia, 10-20 parts of Chinese magnoliavine fruit, 10-20 parts of fragrant solomonseal rhizome, 10-20 parts of rehmannia root and 20-30 parts of ramie root.
Preferably, the first pharmaceutical composition is composed of the following raw material medicines in parts by weight:
20 parts of cherokee rose root, 20 parts of garden burnet root, 20 parts of Japanese notoginseng, 10 parts of raspberry, 30 parts of henbane root, 10 parts of dragon bone, 10 parts of pollen, 10 parts of weeping forsythia capsule, 10 parts of Chinese magnoliavine fruit, 10 parts of fragrant solomonseal rhizome, 10 parts of radix rehmanniae and 20 parts of ramie root.
Preferably, the first pharmaceutical composition is composed of the following raw material medicines in parts by weight:
30 parts of cherokee rose root, 30 parts of garden burnet root, 30 parts of Japanese notoginseng, 20 parts of raspberry, 50 parts of henbane root, 20 parts of dragon bone, 20 parts of pollen, 20 parts of weeping forsythia capsule, 20 parts of Chinese magnoliavine fruit, 20 parts of fragrant solomonseal rhizome, 20 parts of dried rehmannia root and 30 parts of ramie root.
Preferably, the first pharmaceutical composition is composed of the following raw material medicines in parts by weight:
25 parts of cherokee rose root, 25 parts of garden burnet root, 25 parts of Japanese notoginseng, 15 parts of raspberry, 40 parts of henbane root, 15 parts of dragon bone, 15 parts of pollen, 15 parts of weeping forsythia capsule, 15 parts of Chinese magnoliavine fruit, 15 parts of fragrant solomonseal rhizome, 15 parts of dried rehmannia root and 25 parts of ramie root.
Preferably, the dosage ratios of borax, dried alum, borneol, calomel, pollen and cutch are respectively 1.
Further, the first pharmaceutical composition is added with conventional auxiliary materials to be prepared into an oral preparation; the second pharmaceutical composition is an external preparation.
In the invention:
the cherokee rose root is sour and astringent in taste and neutral in nature, and enters kidney, bladder and large intestine channels, astringes intestines, astringes, strengthens spleen and stomach, reduces urination and stops diarrhea, and strengthens kidney and astringes essence;
sanguisorba is bitter, sour and astringent in taste and slightly cold in nature, enters liver and large intestine channels, cools blood and stops bleeding, and detoxifies and heals sores;
the water pseudo-ginseng is bitter in taste and cold in nature, enters liver, lung and stomach channels, cools blood, detoxifies, removes stasis, diminishes inflammation and relieves pain;
the Rubi fructus has sour and sweet taste and mild nature, and has effects of tonifying kidney, arresting seminal emission, reducing urination, nourishing liver and improving eyesight;
bird seed roots are sweet in taste, slightly bitter and neutral in nature, and can expel wind and remove dampness, induce diuresis to alleviate edema, activate blood and relieve pain;
the dragon bone is sweet and astringent in taste and neutral in nature, has the effects of tonifying heart, liver and kidney channels, relieving convulsion, relieving pain, promoting urination, soothing the nerves, arresting sweating, controlling nocturnal emission, stopping bleeding, astringing intestines, promoting granulation and healing sores;
the pollen is sweet or slightly bitter in taste and slightly cold in nature, enters lung, kidney and channels, is good at clearing lung and stomach excess fire, and has the effects of promoting fluid production and quenching thirst; regulating nervous system, promoting sleep, improving body constitution, improving gastrointestinal function, and promoting digestion;
fructus forsythiae is bitter and slightly pungent in taste and cold in nature, enters heart, lung and small intestine channels, clears away heat and toxic materials, reduces swelling, removes stasis and disperses wind and heat;
the schisandra chinensis is sour, bitter, sweet, pungent and salty in taste, has warm nature, enters lung, heart and kidney channels, astringes and relieves astringency, benefits qi and generates body fluid, tonifies kidney and calms heart;
fragrant solomonseal rhizome, sweet in taste and slightly cold in nature, enters lung and stomach meridians, and has the effects of nourishing yin, moistening dryness, promoting the production of body fluid and quenching thirst;
the dried rehmannia root is sweet and bitter in taste and cold in nature, enters heart, liver and kidney channels, clears heat and promotes fluid, cools blood and stops bleeding;
the ramie root is sweet in taste and cold in nature, and has effects of heart, liver and bladder channels, stopping bleeding, preventing miscarriage, clearing heat, detoxicating and promoting urination;
borax has effects of clearing away heat and toxic materials, relieving swelling, preventing corrosion, and healing sore;
dried alum can eliminate phlegm, dry dampness, check diarrhea, stop bleeding and remove toxicity;
borneol is used for sterilizing, promoting muscle regeneration and detoxifying;
calomelas has effects of killing bacteria, removing toxic substance, killing parasite, relieving itching, promoting urination and removing water retention.
Catechu has effects of promoting granulation, removing toxic substance, promoting blood circulation, relieving pain, stopping bleeding, and promoting fluid production.
The invention has the beneficial effects that: the first pharmaceutical composition is taken orally, and the medicines are combined, so that the first pharmaceutical composition has the effects of reducing blood sugar, clearing heat and removing toxicity, eliminating stasis and relieving pain, removing swelling and pus, warming channels and dispelling cold and eliminating dampness and the like, remarkably improves the blood circulation of feet of a diabetic patient, effectively improves the microcirculation of an ulcer surface, and promotes the healing of the wound of the ulcer surface; the first external medicine composition can directly act on the external wound surface, astringe and promote tissue regeneration, sterilize and disinfect, quickly reduce the area of the wound surface, reduce the infection probability of the wound surface, treat both internally and externally, and combine two phases, so that the ulcerated wound can be healed quickly, the treatment course is shortened, and the treatment effect is improved.
Detailed Description
Reference will now be made in detail to embodiments of the invention, one or more examples of which are described below. Each example is provided by way of explanation, not limitation, of the invention. Indeed, it will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment, can be used on another embodiment to yield a still further embodiment.
It is therefore intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents. Other objects, features and aspects of the present invention are disclosed in or are apparent from the following detailed description. It is to be understood by one of ordinary skill in the art that the present discussion is a description of exemplary embodiments only, and is not intended as limiting the broader aspects of the present invention. The present invention will be further described with reference to the following examples.
Example 1: the medicine for treating diabetic foot comprises a first medicine composition and a second medicine composition, wherein the first medicine composition is composed of the following raw material medicines in parts by weight:
the first pharmaceutical composition is composed of the following raw material medicines in parts by weight:
20-30 parts of cherokee rose root, 20-30 parts of garden burnet root, 20-30 parts of Japanese notoginseng, 10-20 parts of raspberry, 30-50 parts of henbane root, 10-20 parts of dragon bone, 10-20 parts of pollen, 10-20 parts of weeping forsythia, 10-20 parts of Chinese magnoliavine fruit, 10-20 parts of fragrant solomonseal rhizome, 10-20 parts of radix rehmanniae and 20-30 parts of ramie root.
The second medicinal composition is composed of borax, dried alum, borneol, calomel, pollen and cutch;
the dosage ratios of borax, dried alum, borneol, calomel, pollen and catechu are respectively 1.
Example 2: a medicine for treating diabetic foot comprises a first medicine composition and a second medicine composition, wherein the first medicine composition is composed of the following raw medicines in parts by weight:
the first pharmaceutical composition is composed of the following raw material medicines in parts by weight:
30 parts of cherokee rose root, 30 parts of garden burnet root, 30 parts of Japanese notoginseng, 20 parts of raspberry, 50 parts of henbane root, 20 parts of dragon bone, 20 parts of pollen, 20 parts of weeping forsythia capsule, 20 parts of Chinese magnoliavine fruit, 20 parts of fragrant solomonseal rhizome, 20 parts of dried rehmannia root and 30 parts of ramie root.
The second medicinal composition consists of borax, dried alum, borneol, calomel, pollen and cutch;
the dosage ratios of borax, dried alum, borneol, calomel, pollen and cutch are respectively 1.
Example 3: the medicine for treating diabetic foot comprises a first medicine composition and a second medicine composition, wherein the first medicine composition is composed of the following raw material medicines in parts by weight:
the first pharmaceutical composition is composed of the following raw material medicines in parts by weight:
25 parts of cherokee rose root, 25 parts of garden burnet root, 25 parts of Japanese notoginseng, 15 parts of raspberry, 40 parts of henbane root, 15 parts of dragon bone, 15 parts of pollen, 15 parts of weeping forsythia capsule, 15 parts of Chinese magnoliavine fruit, 15 parts of fragrant solomonseal rhizome, 15 parts of dried rehmannia root and 25 parts of ramie root.
The second medicinal composition is composed of borax, dried alum, borneol, calomel, pollen and cutch;
the dosage ratios of borax, dried alum, borneol, calomel, pollen and cutch are respectively 1.
The first pharmaceutical composition of examples 1 to 3 is formulated into oral preparations, such as decoction, or honeyed pills, by adding conventional adjuvants.
For example: the method for decocting the liquid comprises the following steps:
firstly, soaking the raw material medicaments for 10-20 minutes to ensure that the raw material medicaments fully absorb water; secondly, water is added according to the ingredients of the decoction pieces, the dosage, the decoction time, the dose and the like, generally, 3500 to 4000ml of the traditional Chinese medicine is added in 5 doses, and 2000ml of liquid medicine can be obtained; and then, decocting according to the instruction of the decocting machine, and packaging according to the dosage of each time after the decoction is finished.
The second medicinal composition is an external preparation, for example, the second medicinal composition can be external powder, and borax, dried alum, borneol and calomel are ground into powder according to a proportion and uniformly mixed. Changing dressing 1 time per day
Example 4: randomly selecting 78 volunteers diagnosed with diabetic foot from 4 months to 2022 years 2020, wherein the volunteers are classified into 1-3 grades according to Wagner classification standard, 42 males and 36 females are aged at 35-78 years, treating with the composition of the invention of example 3, the first pharmaceutical composition is orally administered with 1 dose of 200ml every day, and is orally administered twice in the morning and afternoon, each time with 100ml, and the second pharmaceutical composition is directly applied to the wound surface and changed for 1 time every day.
15 days is a treatment course, and 3 treatment courses are continued.
The curative effect standard is as follows:
and (3) curing: the local swelling disappears, the ulcer surface is completely healed, and no pain exists;
the effect is shown: the secretion of the wound surface is obviously reduced, the ulcer surface is reduced by more than 60 percent, and the pain is obviously relieved;
the method has the following advantages: the secretion of the wound surface is reduced, the ulcer surface is reduced by 30-50%, and the pain is relieved;
and (4) invalidation: the disease condition remains unchanged.
The treatment results are as follows:
71 patients are cured, 5 patients are obviously treated, 2 patients are treated effectively, the cure rate is 91.05 percent, and the total effective rate is 100 percent.
Example 5: typical case
Case 1: yu Mou, the male is 63 years old, the diabetic course is 6 years old, the ulcer on the left instep is 11 mm multiplied by 28mm, after the continuous treatment of the traditional Chinese medicine composition in the embodiment 3 of the invention is carried out for 5 days, the secretion of the wound surface is obviously reduced, the skin has the convergence sign, and the ulcer is healed after the continuous treatment for 15 days.
Case 2: zhou Mou, female, 71 years old, 10 years old, ulcer appeared in the left and right ankle bones, 12 × 35 and 20 × 29 respectively, and the ulcer surface healed after continuous treatment for 30 days by adopting the treatment of the embodiment 3 of the invention.
Case 3: she Mou, 55 years old, 5 x 7 ulceration of the second toe of the left foot, and the wound surface is basically healed after continuous treatment for 3 days by adopting the treatment of the invention in the embodiment 1.
The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.

Claims (7)

1. The medicine for treating diabetic foot is characterized by comprising a first medicine composition and a second medicine composition, wherein the first medicine composition is prepared from the following raw material medicines in parts by weight:
10-50 parts of cherokee rose root, 10-50 parts of garden burnet root, 10-50 parts of Japanese notoginseng, 5-50 parts of raspberry, 20-70 parts of henbane root, 5-40 parts of dragon bone, 5-40 parts of pollen, 5-40 parts of weeping forsythia, 5-40 parts of Chinese magnoliavine fruit, 5-40 parts of fragrant solomonseal rhizome, 5-40 parts of radix rehmanniae and 10-50 parts of ramie root;
the second medicinal composition consists of borax, dried alum, borneol, calomel, pollen and cutch, and the dosage ratios of the borax, the dried alum, the borneol, the calomel, the pollen and the cutch are respectively as follows: 0.5-2:0.5-2:0.5-2:0.2-1:0.5-2:0.5-2.
2. The drug for treating diabetic foot according to claim 1, wherein the first pharmaceutical composition is composed of the following raw material drugs in parts by weight:
20-30 parts of cherokee rose root, 20-30 parts of garden burnet root, 20-30 parts of Japanese notoginseng, 10-20 parts of raspberry, 30-50 parts of henbane root, 10-20 parts of dragon bone, 10-20 parts of pollen, 10-20 parts of weeping forsythia, 10-20 parts of Chinese magnoliavine fruit, 10-20 parts of fragrant solomonseal rhizome, 10-20 parts of radix rehmanniae and 20-30 parts of ramie root.
3. The drug for treating diabetic foot according to claim 2, wherein the first pharmaceutical composition is composed of the following raw material drugs in parts by weight:
20 parts of cherokee rose root, 20 parts of garden burnet root, 20 parts of Japanese notoginseng, 10 parts of raspberry, 30 parts of henbane root, 10 parts of dragon bone, 10 parts of pollen, 10 parts of weeping forsythia capsule, 10 parts of Chinese magnoliavine fruit, 10 parts of fragrant solomonseal rhizome, 10 parts of radix rehmanniae and 20 parts of ramie root.
4. The drug for treating diabetic foot according to claim 2, wherein the first pharmaceutical composition is composed of the following raw material drugs in parts by weight:
30 parts of cherokee rose root, 30 parts of garden burnet root, 30 parts of Japanese notoginseng, 20 parts of raspberry, 50 parts of henbane root, 20 parts of dragon bone, 20 parts of pollen, 20 parts of weeping forsythia capsule, 20 parts of Chinese magnoliavine fruit, 20 parts of fragrant solomonseal rhizome, 20 parts of dried rehmannia root and 30 parts of ramie root.
5. The drug for treating diabetic foot according to claim 2, wherein the first pharmaceutical composition is composed of the following raw material drugs in parts by weight:
25 parts of cherokee rose root, 25 parts of garden burnet root, 25 parts of Japanese notoginseng, 15 parts of raspberry, 40 parts of henbane root, 15 parts of dragon bone, 15 parts of pollen, 15 parts of weeping forsythia capsule, 15 parts of Chinese magnoliavine fruit, 15 parts of fragrant solomonseal rhizome, 15 parts of dried rehmannia root and 25 parts of ramie root.
6. The medicament for treating diabetic foot according to claim 1, wherein the dosage ratio of borax, dried alum, borneol, calomel, pollen and catechu is 1.
7. The medicament for treating the diabetic foot according to any one of claims 1 to 6, wherein the first pharmaceutical composition is prepared into an oral preparation by adding conventional adjuvants; the second pharmaceutical composition is an external preparation.
CN202211349515.3A 2022-10-31 2022-10-31 Medicine for treating diabetic foot Withdrawn CN115569173A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211349515.3A CN115569173A (en) 2022-10-31 2022-10-31 Medicine for treating diabetic foot

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211349515.3A CN115569173A (en) 2022-10-31 2022-10-31 Medicine for treating diabetic foot

Publications (1)

Publication Number Publication Date
CN115569173A true CN115569173A (en) 2023-01-06

Family

ID=84588843

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211349515.3A Withdrawn CN115569173A (en) 2022-10-31 2022-10-31 Medicine for treating diabetic foot

Country Status (1)

Country Link
CN (1) CN115569173A (en)

Similar Documents

Publication Publication Date Title
CN101703651B (en) Medicament for treating diabetic gangrene
CN102579915B (en) Medicine for treating wound non-healing of diabetics
CN114886967A (en) External traditional Chinese medicine composition for promoting tissue regeneration and preparation method thereof
CN115569173A (en) Medicine for treating diabetic foot
CN108635362B (en) Pharmaceutical composition for treating diabetic foot
CN113491732A (en) Granulation promoting and wound healing Chinese herbal medicine external ointment for treating pyocutaneous disease wounds
CN103212000B (en) Preparation method of drug treating unhealed wound of diabetic patient
CN112156225A (en) Chitosan or and algal polysaccharide composite biological matrix liquid dressing gel preparation and preparation method thereof
CN109045204A (en) A kind of herb liquid and preparation method thereof for treating burn and scald
CN108066466A (en) A kind of Chinese medicine composition for treating burn and scald and preparation method and application
CN103655854A (en) External application medicine for treating phlebitis caused by intravenous infusion and using method thereof
CN110585379A (en) External application medicine for treating dermatitis
CN106344837A (en) Traditional Chinese medicine composition for treating dermatophytosis
CN1075730C (en) Wind evil-dispelling, meridian passage-dredging and pus-drawing out medicine powder
CN113144018B (en) Traditional Chinese medicine composition for treating blunt injury of soft tissues and extract and application thereof
CN101983681A (en) Medicament for treating abnormal leucorrhea
CN1236798C (en) External medicine for treating bone tuberculosis
CN110403995B (en) Traditional Chinese medicine composition for treating superficial phlebitis and preparation, use methods and application thereof
CN108245577B (en) Ointment for relieving pain, eliminating swelling and promoting tissue regeneration of burn and preparation method thereof
CN105833074A (en) Traditional Chinese medicine composition for treating oral ulcer
CN105327290A (en) Traditional Chinese medicine for external use for treating diabetic gangrene and preparation method thereof
CN105832909A (en) Traditional Chinese medicine preparation for treating necrotic ulcer of skin
CN111991506A (en) Traditional Chinese medicine composition for treating diabetic foot by oral administration and external application
CN111905052A (en) Traditional Chinese medicine composition for treating diabetic foot by oral administration and external application
CN1375306A (en) Sanhuanggao ointment as externally used medicine for treating burns and scalds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20230106